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Abstract
Lung development is a complex and finely balanced process. Yet the lung has a relatively limited repertoire of
responses to injury, which, depending on severity of the injury and developmental stage and susceptibility of the
lung, culminate in stopping development, followed by more or less successful repair or alternatively in fibrosis.
Unlike fetal skin, which heals scarlessly early in gestation, but scars later in gestation and increasingly so postnatally,
the damaged fetal lung does heal, but not very well. Thus lung injury appears to entrain a default developmental/
repair mechanism involving increased amounts of activated TGF beta ligand signaling. When this occurs prior to or
very early in the process of alveolarization, excessive TGF beta ligand inhibits further alveolarization, a disease
process phenotype that has been termed Bronchopulmonary Dysplasia in extreme human prematurity. However,
once alveolarization is sufficiently advanced as in mid to late gestation fetal monkey, late gestation human or adult
mouse, rat or human lung, excessive TGF beta signaling results in pulmonary fibrosis. Recently we have further
shown that FGF10 signaling, a process that is necessary for distal lung morphogenesis, can also antagonize
bleomycin-induced lung fibrosis in adult mice by a mechanism involving inhibition of active TGF beta ligand
bioavailability. We therefore suggest that lung development, repair and fibrosis have many fundamental
mechanisms in common, that potentially can be manipulated using cells or soluble factors that optimize the
alveolar milieu to prevent and possibly even to reverse lung fibrosis.
Lung development is a complex and finely balanced pro-
cess of self assembly that is driven by crosstalk between
the epithelium, the mesenchyme, the vasculature within
it, smooth muscle, nerves and other crtical tissue compo-
nents including matrix proteins and proteoglycans,
together with carefully calibrated responses to physical
forces including luminal hydraulic peristalsis [1,2]. Yet
the lung has a relatively limited repertoire of responses to
injury, which, depending on severity of the injury and
developmental stage and susceptibility of the lung, culmi-
nate in stopping development, followed by more or less
successful repair or alternatively in fibrosis.
In extremely premature human infants (<28 weeks
gestation), alveolarization has barely begun. Removal of
airway liquid and exposure of the lung to air or oxygen
breathing, even with artificial surfactant therapy fre-
quently results in a form of alveolar hypoplasia termed
“new” Bronchopulmonary dysplasia (BPD). Whereas
before the advent of surfactant therapy, delivery at >30
weeks and ventilation with oxygen to treat acute respira-
tory distress syndrome resulted in a more classical form
of BPD characterized by emphysema and interstitial
fibrosis. Long-term follow up of human prematures has
shown that their lungs do grow. However, in severe cases
of both old and the more newly recognized forms BPD,
chronic desaturation requiring home oxygen or even
home ventilation is a continuing management issue.
Nevertheless in milder cases of prematurity, lung devel-
opment appears to become relatively normal, with the
notable exception that children identified with BPD who
survive over 5 years of age destaurate on maximal exer-
cise [3], and there is a markedly increased incidence of
wheezing in these children as well. Moreover, their pul-
monary reserve in the face of intercurrent viral infection
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any medium, provided the original work is properly cited.is clearly limited. Thus, unlike the fetal skin, which heals
scarlessly early in gestation, but scars later in gestation,
and increasingly so postnatally, the damaged human fetal
lung does appear to heal, but not necessarily do so very
well. In fact a few of the early, larger premature babies
who survived Wilson-Mikity syndrome, a BPD-like lung
disease, are now showing up at 30 years plus follow up
with severe early onset emphysema/COPD like pictures
on chest radiography. Of course some of them may be
mutant for one of the rare alleles that cause surfactant
protein deficiency or misfolding, which themselves result
in chronic alveolar epithelial endoplasmic reticulum
stress syndromes [4].
Postnatally the lung continues to grow, adding alveolar
complexity to achieve the final ventilation-perfusion sur-
face area of a tennis court by young adulthood. However,
past middle age, FEV1 falls inexorably by 2-3% per year so
that by 120 years of age even super athletes will have
COPD/senile emphysema-like restrictive lung disease
[5,6].
The impact of lung injury on lung function has been
studied quite extensively in animals. In mice and rats, in
which alveoalrization occurs postnatally, exposure to
hyperoxia or to advector expressing active TGFbeta1
ligand results in a similar BPD-like picture of alveolar
hypolplasia [7]. Interestingly though, in fetal monkeys
wherein alveolarization is already well advanced in utero,
injection of advector expressing active TGFbeta1 ligand
results in aggressive fibrosis that extends through the lung,
probably via the interstitial reticulum, as far as the visceral
pleura, wherein it causes extensive pleural thickening [8].
This phenotype is very similar to the aggressive interstitial
fibrosis caused by injection or inhalation of advector
expressing active TGFbeta1 ligand in adult rats [9]. How-
ever severe pleural thickening is not common in human
BPD.
We as well as others others have shown previously that
TGF beta signaling plays a key physiological role in lung
development as well as alveolar epithelial repair [10].
Therefore lung injury appears to entrain a default repair
mechanism involving increased amounts of activated TGF
beta ligand signaling. When this occurs prior to or very
early in the process of alveolarization, excessive TGF beta
signaling inhibits further alveolarization, a disease process
phenotype strikingly similar to the one that has been
termed Bronchopulmonary Dysplasia in extreme human
prematurity. However, once alveolarization is sufficiently
advanced as in fetal monkey, or in late gestation human or
adult mouse, rat or human lung, excessive TGF beta sig-
naling results in pulmonary fibrosis. This, insight led us to
coin the “Goldilocks” hypothesis: that TGF beta signaling
has to be “just right” for lung development to function
correctly prenatally as well as postnatally.
Interestingly, TGF beta1 ligand signaling also has an
important role in suppressing excessive tissue inflamma-
tion, as demonstrated in the TGFbeta1 null mouse,
which dies of pneumonia or excessive inflammation of
other organs. Somewhat similarly null mutation of
Smad3 a key downstream signal transduction element in
the canonical TGF beta pathway impairs alveolarization,
giving rise to a primary hypo-alveolar phenotype,
together with subsequent activation of MMP9, which
leads to an early onset destructive emphysema pheno-
type [11,12]. These forms of emphysema are exacerbated
by exposure of young mutant mice to sidestream
tobacco smoke. Other mutations in TGF beta binding
protein genes such as LTBP4, endoglyn or fibrillin result
in lung epithelial or vascular malformations.
Probably because they contain intact genomes and are
therefore smart, stem cell based therapies are beginning
to show promise as methods to ameliorate lung injury
and possibly fibrosis. However, the danger that the
abnormal fibrotic tissue milieu may induce them to
express collagen and other pro-fibrotic proteins remains
at least a theoretical concern. Nevertheless stem cells
derived from discarded fetal materials may have some
theoretical advantages. We have enjoyed some prelimin-
ary success using human amniotic fluid derived stem and
progenitor cells to ameliorate the tissue milieu in various
injury models, including the lung and the kidney [13].
Gremlin is an intracellular as well as extracellular BMP
inhibitor ligand binding protein that inhibits the function
of BMP4 in the developing lung [14]. Interestingly,
Gremlin is over-expressed in cases of adult idiopathic
pulmonary fibrosis (IPF) [15], its level of expression can
differentiate among severities of IPF and it does indeed
antagonize BMP signaling and thus potentiates pulmon-
ary fibrosis [16,17].
We have also recently shown that FGF10 signaling, a
process that is necessary for distal lung morphogenesis,
can also antagonize bleomycin-induced lung fibrosis in
adult mice, by a mechanism involving inhibition of
active TGF beta ligand bioavailability and hence less tis-
sue inflammation [18]. This suggests that modification
of the alveolar milieu may also be possible, using soluble
developmental factors that could ameliorate or reverse
TGFbeta mediated fibrosis.
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